Johnson & Johnson (NYSE:JNJ) Shares Sold by Oregon Public Employees Retirement Fund

Oregon Public Employees Retirement Fund lessened its stake in Johnson & Johnson (NYSE:JNJ – Get Rating) by 4.7% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 696,152 shares of the company’s stock after selling 34,091 shares during the quarter. Johnson & Johnson comprises about 1.6% of Oregon Public Employees Retirement Fund’s holdings, making the stock its 4th largest holding. Oregon Public Employees Retirement Fund’s holdings in Johnson & Johnson were worth $113,723,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Waterfront Wealth Inc. boosted its holdings in Johnson & Johnson by 4.5% in the 3rd quarter. Waterfront Wealth Inc. now owns 3,653 shares of the company’s stock worth $632,000 after acquiring an additional 157 shares during the period. Tobam boosted its stake in shares of Johnson & Johnson by 284.4% during the 3rd quarter. Tobam now owns 72,528 shares of the company’s stock valued at $11,848,000 after buying an additional 53,659 shares during the last quarter. Hudock Inc. boosted its stake in shares of Johnson & Johnson by 8.6% during the 3rd quarter. Hudock Inc. now owns 7,840 shares of the company’s stock valued at $1,280,000 after buying an additional 621 shares during the last quarter. Lee Financial Co boosted its stake in shares of Johnson & Johnson by 8.3% during the 3rd quarter. Lee Financial Co now owns 2,765 shares of the company’s stock valued at $451,000 after buying an additional 211 shares during the last quarter. Finally, Crossmark Global Holdings Inc. boosted its stake in shares of Johnson & Johnson by 3.9% during the 3rd quarter. Crossmark Global Holdings Inc. now owns 50,207 shares of the company’s stock valued at $8,202,000 after buying an additional 1,867 shares during the last quarter. Hedge funds and other institutional investors own 67.94% of the company’s stock.

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $168.31 on Wednesday. Johnson & Johnson has a 1-year low of $155.72 and a 1-year high of $186.69. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.43 and a quick ratio of 1.18. The business’s fifty day moving average price is $175.98 and its two-hundred day moving average price is $171.06. The firm has a market capitalization of $440.04 billion, a PE ratio of 23.44, a P/E/G ratio of 3.21 and a beta of 0.56.

Johnson & Johnson (NYSE:JNJ – Get Rating) last issued its quarterly earnings results on Tuesday, January 24th. The company reported $2.35 EPS for the quarter, beating analysts’ consensus estimates of $2.23 by $0.12. The company had revenue of $23.71 billion for the quarter, compared to analyst estimates of $23.90 billion. Johnson & Johnson had a return on equity of 35.37% and a net margin of 19.95%. The company’s quarterly revenue was down 4.4% compared to the same quarter last year. During the same period last year, the company earned $2.13 earnings per share. On average, research analysts expect that Johnson & Johnson will post 10.04 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 7th. Stockholders of record on Tuesday, February 21st will be issued a dividend of $1.13 per share. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.69%. The ex-dividend date of this dividend is Friday, February 17th. Johnson & Johnson’s dividend payout ratio (DPR) is 62.95%.

Insider Activity

In related news, VP Thibaut Mongon sold 35,246 shares of the firm’s stock in a transaction dated Friday, November 4th. The stock was sold at an average price of $171.18, for a total transaction of $6,033,410.28. Following the completion of the transaction, the vice president now owns 40,133 shares of the company’s stock, valued at $6,869,966.94. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In related news, VP Thibaut Mongon sold 35,246 shares of the firm’s stock in a transaction dated Friday, November 4th. The stock was sold at an average price of $171.18, for a total transaction of $6,033,410.28. Following the completion of the transaction, the vice president now owns 40,133 shares of the company’s stock, valued at $6,869,966.94. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Joseph J. Wolk sold 14,781 shares of the firm’s stock in a transaction dated Tuesday, December 13th. The shares were sold at an average price of $179.60, for a total value of $2,654,667.60. Following the transaction, the chief financial officer now directly owns 35,812 shares of the company’s stock, valued at approximately $6,431,835.20. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 233,611 shares of company stock valued at $40,960,735. Company insiders own 0.35% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the company. Barclays assumed coverage on Johnson & Johnson in a research note on Monday, October 17th. They set an “equal weight” rating and a $175.00 target price for the company. Atlantic Securities dropped their price target on Johnson & Johnson from $165.00 to $160.00 and set a “neutral” rating on the stock in a research report on Wednesday, October 19th. Credit Suisse Group started coverage on Johnson & Johnson in a research report on Thursday, November 17th. They set a “neutral” rating and a $170.00 price target on the stock. Morgan Stanley dropped their price target on Johnson & Johnson from $178.00 to $176.00 and set an “equal weight” rating on the stock in a research report on Tuesday, December 6th. Finally, Citigroup upped their price target on Johnson & Johnson from $198.00 to $205.00 and gave the company a “buy” rating in a research report on Monday, December 12th. Seven analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $181.75.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.